| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| EXAGEN INC. | Director | Stock Option(right to buy) | 9,000 | $32,220 | $3.58 | 09 Jun 2023 | Direct |
| Reneo Pharmaceuticals, Inc. | Chief Development Officer | Common Stock | 0 | $6.28 | 14 Jul 2021 | Direct | |
| Reneo Pharmaceuticals, Inc. | Chief Development Officer | Stock option (right to buy) | 0 | 08 Jul 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| XGN | EXAGEN INC. | 09 Jun 2023 | 1 | $0 | 4 | Director | 13 Jun 2023, 16:35 |
| XGN | EXAGEN INC. | 16 Jun 2022 | 1 | $0 | 4 | Director | 21 Jun 2022, 08:34 |
| XGN | EXAGEN INC. | 03 Sep 2021 | 1 | +$14,020 | 4 | Director | 07 Sep 2021, 08:25 |
| RPHM | Reneo Pharmaceuticals, Inc. | 14 Jul 2021 | 1 | -$949,756 | 4 | Chief Development Officer | 15 Jul 2021, 17:33 |
| RPHM | Reneo Pharmaceuticals, Inc. | 08 Jul 2021 | 2 | +$220,120 | 4 | Chief Development Officer | 09 Jul 2021, 18:52 |
| XGN | EXAGEN INC. | 17 Jun 2021 | 1 | $0 | 4 | Director | 21 Jun 2021, 08:38 |